SOS2 and lung carcinoma: Additionally, phosphoproteomic analysis of ALK-positive lung cancer cells with or without gilteritinib treatment revealed that gilteritinib significantly decreased phosphorylation of ALK and its adapter proteins such as IRS1/2, SOS2, or SH2B1.